Kuratiert · Gesundheit

Biotech

Von InspectStocksPublished 14. Okt. 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Mit Hilfe eines KI-Modells gruppiert und von unserer Redaktion geprüft. Die Zeile unter jedem Unternehmen sagt, warum es hier steht.

Download image

Karten Stufen

Aktienkurse sind die Schlusskurse vom 11. Nov. 2026, aus dem IEX-Börsenfeed.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0 %

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap 138,7B $P/E 35,22
547,02 $+26,0 %1Y
Since added +12,7 %
B+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
13B $+10,5 %
Profit
4B $+8,2 %
Free cash flow
3,2B $-4,0 %
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap 101,3B $P/E 21,18
959,45 $+41,5 %1Y
Since added +27,4 %
C+
Wachstum und Cash
Wächst
Business trend
Beschleunigt
Business quality
Stark
Getting better
Verbessert sich
Revenue
16,9B $+18,6 %
Profit
4,8B $+5,2 %
Free cash flow
3,8B $-9,4 %
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap 210,5B $Kein KGV (operativer Verlust)
169,73 $+40,9 %1Y
Since added +14,8 %
A
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
31B $+6,5 %
Profit
-3,9B $-147,6 %
Free cash flow
13,8B $+50,4 %
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap 21,4B $P/E 68,58
159,80 $-64,7 %1Y
Since added -28,6 %
B+
Wachstum und Cash
Wächst kräftig
Business trend
Verlangsamt
Business quality
Stark
Getting better
Verbessert sich
Revenue
3,7B $+65,2 %
Profit
2,6B $+2.136,9 %
Free cash flow
465,4M $+1.192,7 %
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap 37,5B $P/E 109,22
253,39 $+56,9 %1Y
Since added +10,7 %
A
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Solide
Getting better
Gemischt
Revenue
10,3B $+2,3 %
Profit
347,5M $-78,4 %
Free cash flow
2,1B $-10,1 %
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap 26,5B $Kein KGV (operativer Verlust)
120,64 $-37,9 %1Y
Since added +24,7 %
C-
Wachstum und Cash
Wächst
Business trend
Stabil
Business quality
Schwach
Getting better
Gemischt
Revenue
1,5B $+240,0 %
Profit
-605,6M $+48,8 %
Free cash flow
-627,6M $+30,7 %
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap 25,4B $P/E 22,48
595,58 $+29,0 %1Y
Since added +9,6 %
C+
Wachstum und Cash
Wächst kräftig
Business trend
Verlangsamt
Business quality
Stark
Getting better
Verbessert sich deutlich
Revenue
3,2B $+1,9 %
Profit
1,2B $-3,2 %
Free cash flow
867,2M $-22,7 %
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap 17,6B $P/E 25,87
174,35 $+18,7 %1Y
Since added +29,0 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Beschleunigt
Business quality
Stark
Getting better
Verbessert sich
Revenue
3,7B $+38,0 %
Profit
702,5M $+64,1 %
Free cash flow
1B $+75,3 %
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap 100,6B $Kein KGV (operativer Verlust)
248,70 $+831,1 %1Y
Since added +15,0 %
C-
Wachstum und Cash
Wächst
Business trend
Beschleunigt
Business quality
Schwach
Getting better
Verschlechtert sich
Revenue
2,5B $+13,1 %
Profit
-2,8B $+10,5 %
Free cash flow
-2B $+25,7 %
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap 11,3B $No P/E
58,32 $+5,4 %1Y
Since added +7,3 %
B
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
3,7B $+18,1 %
Profit
-19,1M $-103,7 %
Free cash flow
557,9M $-33,0 %
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap 24,9B $P/E 65,01
122,23 $+12,9 %1Y
Since added +12,6 %
C
Gewinn und Buchwert
Wächst
Business quality
Gemischt
Getting better
Verbessert sich deutlich
Revenue
6B $+24,9 %
Profit
403,4M $-66,1 %
Free cash flow
892,1M $No comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap 17,3B $P/E 21,17
70,71 $+62,2 %1Y
Since added +18,8 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
2,5B $+9,1 %
Profit
885,1M $+30,6 %
Free cash flow
1,2B $+48,9 %
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap 22B $Kein KGV (operativer Verlust)
87,64 $-21,5 %1Y
Since added -1,5 %
F
Wachstum und Cash
Gemischt
Business trend
Schrumpfend
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
2,7B $-23,2 %
Profit
-1,6B $-157,7 %
Free cash flow
314M $+456,5 %
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap 15,9B $P/E 80,84
248,18 $+81,5 %1Y
Since added +18,0 %
A
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
4,7B $+13,5 %
Profit
206M $+155,9 %
Free cash flow
1,6B $+21,3 %
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap 11,6B $P/E 25,36
101,69 $+44,0 %1Y
Since added -7,2 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
1,8B $+45,0 %
Profit
485,4M $-18,5 %
Free cash flow
885,9M $+47,1 %
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap 16,1B $Kein KGV (operativer Verlust)
259,10 $+30,1 %1Y
Since added +16,0 %
D
Gewinn und Buchwert
Gemischt
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
1,2B $+113,4 %
Profit
-254,8M $+39,7 %
Free cash flow
-293,2M $+54,2 %
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap 15,5B $Kein KGV (operativer Verlust)
79,53 $+20,1 %1Y
Since added +25,6 %
B
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Gemischt
Getting better
Verschlechtert sich
Revenue
945,5M $+167,3 %
Profit
-573,8M $+28,6 %
Free cash flow
-369,8M $+36,9 %
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap 8,2B $P/E 58,68
74,52 $-4,9 %1Y
Since added -36,7 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Beschleunigt
Business quality
Stark
Getting better
Gemischt
Revenue
963,6M $+30,0 %
Profit
162,3M $+52,9 %
Free cash flow
194,6M $+19,2 %
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap 9,2B $P/E 41,90
308,82 $+52,1 %1Y
Since added -3,9 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
470M $+26,0 %
Profit
225,2M $+13,2 %
Free cash flow
310,1M $+87,3 %
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.